Will have to cover at some point and next week is ASCO where all the results will be discussed. I feel for those that didn't sell yesterday but i still think this drug will have another run GL2ALL
Yeah i have been following this company for a while now. I got in at .86 because i thought their pipeline was way under priced considering how many drugs they had. I look forward to ASCO so we can get the rest of the story, GL2ALL
Everything looks good going into phase III Over the last couple of days we have seen a rebound in pricee and vol. We should see more gains as we get nearer the ASCO event at the end of the month. GL 2 all who have hung in there, Our day bis getting close. Mike
Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting
- Updated results from coBRIM phase 3 pivotal trial show median progression-free survival of one year for patients with BRAF V600 mutation-positive advanced melanoma –
- Additional data from phase 1b BRIM7 study showed 61 percent of patients who had not been previously treated with a BRAF inhibitor were alive after two years -
- Cobimetinib for use in combination with vemurafenib is the subject of pending U.S. and European regulatory applications, with U.S. PDUFA date of August 11, 2015 -
May 30, 2015 07:30 AM Eastern Daylight Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis Inc. (NASDAQ:EXEL) today announced updated positive results for cobimetinib, an Exelixis-discovered investigational compound, in combination with vemurafenib for the treatment of patients with previously untreated BRAF V600 mutation-positive advanced melanoma. Updated data from coBRIM (Abstract #9006), the phase 3 pivotal trial conducted by Exelixis’ collaborator Genentech, a member of the Roche Group, showed the combination helped patients with previously untreated BRAF V600 mutation-positive advanced melanoma live a median of one year (12.3 months) without disease progression or death, compared to 7.2 months with vemurafenib alone (hazard ratio [HR] = 0.58, 95% confidence interval [CI] 0.46-0.72). Data from a second trial, the phase 1b BRIM7 study (Abstract #9020), showed that treatment with the combination resulted in a median overall survival of more than two years (28.5 months) for patients without prior BRAF inhibitor treatment. Both data sets will be presented at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held this week in Chicago, Illinois.
“The updated results for the combination of cobimetinib and vemurafenib, including a median progression-free s
Not to many early stage bio companies start out with $50.00 dollar pipelines. They tend to build on their starters and add new ones along the way. I have been in ACAD since below $2.00 and in the last two years it has crept up to above 45 and currently trading in the mid to high 30 range. AVEO has all the tools to continue the climb and only time will tell what is in the future. I have been in AVEO since .86 and see no reason to sell a share and will add on any large volume breakout above 2.02 GL2ALL
This has been in a slow and steady accumulation mode for a month now on a great pipeline, It's has a Number 1 strong buy rating by Zacks so i see nothing that point at a boiler room. I have been in this since .86 and plan on adding if anything GL2ALL
The only thing that is relentless is your dribble. AVEO has made a steady climb and only crossed 2.00 yesterday so your post are as informative as you are intelligent
Your down .09 and your nervous. I was in VLTC since 2.00 which is another Icahn stock, Check out that chart and maybe you will feel better
This is a perfect example of a stock to just put away and not get caught up in all the day to day BS that stocks like this tend to get. I will also say that while i don't know what, Carl Icahn has some reason to be in this and i am sure it is not to lose money. GL2ALL
This will be like Ebola, All of a sudden one day the world will wake up and go into panic mode. This is a buy and hold and don't get caught up in all the off topic noise. GL2ALL
From 1:30 to 2:30 ENZN was trading in the top 5 as far as volume goes. During this same period we saw the price turn positive which shows accumulation. Those who sold earlier in the day will have regrets over the next few weeks. GL2ALL
How come it's always the truly stupid that feel they can educate others? The problem with your thesis is that there is a difference between which drugs can be used between egg layers and food chickens due to the fact the amount of medicine that ends up in the egg compared to the meat.
rther study details as provided by Prima BioMed Ltd:
Primary Outcome Measures:
To evaluate the safety of Cvac administration in this population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Progression Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
For eligible patients that have completed or terminated the study, the collection of Overall Survival data will continue through October 2015.
Evaluation of immunologic parameters subsequent to Cvac administration. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Study Start Date: June 2010
Estimated Study Completion Date: December 2014
Don't post till you know what you are talking about! Like i said before (KID)
Working gas in storage was 1,512 Bcf as of Friday, March 6, 2015, according to EIA estimates. This represents a net decline of 198 Bcf from the previous week. Stocks were 483 Bcf higher than last year at this time and 225 Bcf below the 5-year average of 1,737 Bcf. In the East Region, stocks were 162 Bcf below the 5-year average following net withdrawals of 104 Bcf. Stocks in the Producing Region were 128 Bcf below the 5-year average of 683 Bcf after a net withdrawal of 78 Bcf. Stocks in the West Region were 65 Bcf above the 5-year average after a net drawdown of 16 Bcf. At 1,512 Bcf, total working gas is within the 5-year historical range.
I just bought it and put it away and am not worried about the "Big Selloff" of .05 cents. since in a year from now? It will be up a lot more and that is all i am worried about not nickels and Dimes; Thats for kids GL2ALL
Just read some fool who posted that Carl is praying he can con some home gamers into buying his shares. Since he bought it in the last quarter of last year and it was trading close or above 1.00 or higher i guess he needs us to buy it so he can make .25 to stay solvent. Icahn doesn't buy anything for the quick buck. He buys companies he knows will do good. JUst look at VLTC from .65 to over $16.00 in less than a few months, I am in that and while i don't know what he knows i am willing to play along. It has worked great so far. GL2ALL
Considering the sector selloff BIOC has managed to shrug a lot of it off. I believe that those who are willing to hang in there will be rewarded in the near future, Even with the selling the vol has been light. GL2ALL